µ²ºc¦¡ |
|
(+)-(S)-N-methyl-£^-(1-naphthyloxy)-2-thiophenepropylamine hydrochloride
|
UpToDate |
UpToDate ³sµ²
|
ÃIJz§@¥Î |
|
Duloxetine©ó¤HÅ骺§Ü¼~Æ{¡B¤¤¼Ï©Ê¯kµh§í¨î¤Î§ÜµJ¼{ªº½T¹ê§@¥Î¾÷Âऴ¥¼ª¾¡A¬Û«H³o¨Ç§@¥Î»P¨ä¼W±j¤¤¼Ï¯«¸g¤§¦å²M¯À¬¡©Ê(serotonergic)»P¥¿µÇ¤W¸¢¯À¬¡©Ê(noradrenergic)¦³Ãö¡C
|
¾AÀ³¯g |
|
«Æ{¯g¡B¿}§¿¯f¶gÃ䯫¸gµh¡B¼sªx©ÊµJ¼{¯g¡C
|
¥Îªk¥Î¶q |
|
¥»«~À³¤@¤Ñ¨Ï¥Î¤@¦¸¡A¤£¶·¦Ò¼{¶i¹»P§_¡C
|
ÃİʤO¾Ç |
|
Duloxetine¤§±Æ°£¥b°I´Á¬ù12¤p®É(8-17¤p®É)¡C©óªvÀø¾¯¶q½d³ò¤º¡A¨äÃİʩʽè»P¾¯¶q¦¨¥¿¤ñ¡C¤@¯ë§ëÃÄ3¤Ñ«á¹Féw¦å¼ß¿@«×¡CDuloxetine¥Dn¸g¨xŦªº¤GÓP450²§ºc酶(CYP2D6¤ÎCYP1A2)¥NÁ±ư£¡C
|
°Æ§@¥Î |
|
äú¤ß¡B¤f°®¡B¶ÝºÎ¡B«K¯µ¡B¹¼¤°§C¡B¦h¦½¡C
|
¥æ¤¬§@¥Î |
|
CYP1A2»PCYP2D6t³dduloxetineªº¥NÁ 1. CYP1A2§í¨î¾¯¨k©Ê¨ü¸ÕªÌ(14¦ì)¨ÖªAduloxetine 60mg»PCYP1A2§í¨î¾¯fluvoxamine 100mg¡Aduloxetine¥þ¨¼ÉÅS¶q(AUC)¼W¥[¬ù6¿¡A³Ì°ª¦å¤¤¿@«×(Cmax)¼W¥[¬ù2.5¿¡Aduloxetine¥b°I´Á(t1/2)¼W¥[¬ù3¿¡C¨ä¥L§í¨îCYP1A2¥NÁ¬¡©ÊªºÃĪ«¥]¬Acimetidine»PquinoloneÃþ§Ü¥Í¯À¡A¦pciprofloxacin»Penoxacin¡C 2. CYP2D6§í¨î¾¯¨Ö¥Îduloxetine (40mg¤@¤Ñ¤@¦¸)»Pparoxetine (20mg¤@¤Ñ¤@¦¸)·|¼W¥[duloxetine AUC¬ù60% ¥B±À´úparoxetine¾¯¶q·U°ª¡A§í¨î§@¥Î·U©úÅã¡CÃþ¦üªº§@¥Î¥i¯àµo¥Í©ó»P¨ä¥L±j®ÄCYP2D6§í¨î¾¯¨Ö¥Î(¦pfluoxetine¡Aquinidine)¡C 3. ¦P®É§í¨îCYP1A2¤ÎCYP2D6ªº±¡§Î 14¦ìCYP2D6¥NÁÂ¥\¯à¤£¨¬ªº¨ü¸ÕªÌ¡A¨ÖªAduloxetine 40mg¤@¤Ñ¤G¦¸»P±j®ÄCYP1A2§í¨î¾¯fluvoxamine 100mg¡Aµo²{duloxetine¤§¥þ¨¼ÉÅS¶q(AUC)»P³Ì°ª¦å¤¤¿@«×(Cmax)¬Ò¼W¥[6¿¡C 4. ¼vÅT¤î¦å¤ÏÀ³ªºÃĪ«(¦pNSAIDs¡BAspirin¤ÎWarfarin)
|
¸T§Ò |
|
³æÓi®ñ¤Æ×Q§í¨î¾¯(MAOI)¡G ¦X¨ÖCymbalta©Î¦b°±¤îCymbaltaªvÀø«á5¤Ñ¤º¡A¸T¤î¨Ï¥ÎMAOI¥HªvÀøºë¯«¯e±w¡A¦]¬°·|³y¦¨¦å²M¯À¯gÔ¸sªº·ÀI¼W¥[¡C°±¤îMAOIªvÀø«á14¤Ñ¤º¡A¥ç¸T¥ÎCymbalta¨ÓªvÀøºë¯«¯e±w¡C¥Ñ©ó·|³y¦¨¦å²M¯À¯gÔ¸sªº·ÀI¼W¥[¡A¥¿¦b±µ¨üMAOI¡]¨Ò¦plinezolid»PÀR¯ßª`®g¨È¥ÒÂÅ¡^ªvÀøªº¯f±w¡A¥ç¸T¥ÎCymbalta¡C ¥¼±±¨î¤§¯U¨¤©Ê«C¥ú²´¡G ªA¥ÎCymbalta¥i¯à¼W¥[´²Àûªº·ÀI¡A¦]¦¹±w¦³¥¼±±¨î¤§¯U¨¤©Ê«C¥ú²´ªº¯f±wÀ³ÁקKªA¥Î¥»ÃÄ¡C
|
µ¹¥I³W©w |
|
1.1.8.Duloxetine¡]¦pCymbalta¡^¡G(102/8/1¡B105/2/1) 1.¨Ï¥Î©ó¿}§¿¯f¨Öµo©PÃ䯫¸g¯fÅܨè㦳Á{§É¯«¸g¯kµh (neuropathic pain)¡A¥B²Å¦X¥H¤U±ø¥ó¡G (1)¸g¯«¸g¬ì±M¬ìÂå®v¶EÂ_©Î¸g¯«¸g¶Ç¾É(NCV) ÀˬdÃҹꤧ¦hµo©Ê¯«¸g¯fÅÜ(polyneuropathy)¡C (2)Pain rating scale¡Ù4¤À¡C (3)¤£±o¨Ö¥Î¦PÃþ¾AÀ³¯g¤§ÃÄ«~¡C (4)¨Ï¥Î«áÀ³¨C3Ó¤ëµû¦ô¤@¦¸¡A¨Ã©ó¯f¾ú¤¤°O¸üµû¦ôµ²ªG¡AÕPain rating scale¸û«e¤@¦¸µû¦ô¤§¼ÆÈ¥¼§ïµ½©Î¥¼«ùÄò§ïµ½¡AÀ³¤©°±¤î¨Ï¥Î¡C (5)¨C¤é³Ì¤j¾¯¶q¬°60mg¡C 2. ¨Ï¥Î©óÅÖºû¦Ùµh(fibromyalgia)(105/2/1) (1)»Ý²Å¦XAmerican College of Rheumatology (ACR)¤ÎÁ{§É¸ÕÅç¹êÃÒÅÖºû¦Ùµh¶EÂ_¼Ð·Ç¡G ¢¹.WPI(wide spread pain index)¡Ù7¡BSymptom severity (SS)¡Ù5¥Bpain rating scale¡Ù6¤À©ÎWPI 3-6¡BSS scale¡Ù9¥Bpain rating scale¡Ù6¤À¡C ¢º.¯gª¬«ùÄò¶W¹L¤TÓ¤ë¡C ¢».À³±Æ°£¨ä¥L¯e¯f¦]¯À¡A¨Ã©ó¯f¾ú¸Ô¸ü¡C (2)·Àã§K¬Ì¬ì¡B¯«¸g¤º¬ì¡B´_°·¬ì¡B¯kµh±M¬ì¤Îºë¯«¬ìÂå®v¨Ï¥Î¡A¤£±o¨Ö¥Î¦P¾AÀ³¯g¤§¥¦ÃþÃÄ«~¡C (3)¦p¨Ï¥Î3Ó¤ë«ápain rating scale¥¼´î¤Ö2¤À¥H¤WÀ³¤©°±ÃÄ¡C (4)¯f¾ú¨C3Ó¤ëÀ³°O¸ü¤@¦¸µû¦ôµ²ªG¡A¨C¤é³Ì¤j¾¯¶q¬°60mg¡C
1.2.1.¿ï¾Ü©Ê¦å²M«P¶i¯À¦A§l¦¬§í¨î¾¯ (SSRI)¡B¦å²M«P¶i¯À¤Î¥¿µÇ¤W¸¢¯À¦A§l¦¬§í¨î¾¯ (SNRI)¤Î¨ä¥L§Ü¼~Æ{¾¯¡]duloxetine¡^¡G(88/12/1¡B89/10/1¡B91/5/1¡B92/6/1¡B93/5/1¡B94/2/1¡B94/12/1¡B99/10/1¡B101/7/1¡B107/3/1) ¨Ï¥Î®É¯f¾ú¤WÀ³¸Ô²Óµù©ú¶EÂ_¨Ì¾Ú¤Î¨Ï¥Î²z¥Ñ¡C
|
ª`·N¨Æ¶µ |
|
¦Û±þ¡GºÊ´ú¯fªp´c¤Æ©Î¦Û±þ·ÀI¡C
¨x¬r©Ê¡G¦³¨x°IºÜ¡A¨ä¤¤¦³¨ÇP¦ºªº®×¨Òµo¥Í©ó¥HCymbaltaªvÀøªº¯f±w¤¤¡C·í¯f±w²£¥Í¶À¯n©Î¦³ÃÒ¾ÚÅã¥Ü²£¥ÍÁ{§É¤W©úÅ㪺¨x¥\¯à»Ùê¡AÀ³¸Ó°±¤îCymbaltaªºªvÀøª½¨ì½T»{³y¦¨¤Wz¯e¯fªº¨ä¥L¦]¯À¤~¥i¦A«×¨Ï¥ÎCymbalta¡CCymbalta¤£À³¥Î©óªvÀø¤j¶q¨Ï¥Î°sºëªº¯f±w©ÎºC©Ê¨x¯f¯f±w¡C „P «º¶Õ©Ê§C¦åÀ£¤Î·w³Ö¡G´¿¦³¯f±wªA¥Î¥»Ãĵo¥Í«º¶Õ©Ê§C¦åÀ£¤Î·w³Öªº³ø§i¡C
G±ÆªÅ³t«×ºCªº¯f±w¡GÀ³¤p¤ßÂÔ·V¦a¨Ï¥Î¥»ÃĪvÀø³o¨Ç¯f±w¡C
|
¹L¶q³B²z |
|
Cymbalta¨S¦³¯S©wªº¸Ñ¬r¾¯¡AY«ùÄò¥X²{¦å²M¯À¯gÔ¸sÀ³¦Ò¼{¯S©wªvÀø(¤ñ¦pµ¹¤©cyproheptadine¤Î/©ÎÅé·Å±±¨î)¡CYµo¥Í«æ©ÊªAÃĹL¶q¡A³B²z¤è¦¡À³¦P©ó³B²z¨ä¥¦ÃĪ«¹L¶qªº¤èªk¡C ½T«O©I§l¹D³qºZ¡Aµ¹¤©®ñ®ð¤Î´«®ð¤ä«ù¡CºÊ´ú¤ß¸õ³t²v»P¥Í©R¸ñ¶H¡C¤£«Øij¶Ê¦R¡C¹ïªAÃīᤣ¤[©Î¥X²{¯gª¬ªº¯f¤H¡A¦pªG¦³»Ýn¡A¥i¥H¦b©I§l¹D¦³¾A·í«OÅ@¤U¡A¥H¤j¤Õ®|ªºGºÞ¬~G¡C ¬¡©ÊºÒ¥i¦³®Ä¨îduloxetine©óG¸z¹Dªº§l¦¬¡C§ë»P¬¡©ÊºÒ¥§¡¥i°§CAUC»PCmax¬ù1/3¡AµM¦Ó¬¡©ÊºÒ¹ï¦³¨Çª«½èªº¼vÅT¦³¡C¥Ñ©óduloxetineªº¤À§GÅé¿n¤j¡A¦]¦¹±j¢§Q§¿¡B³zªR¡B¦å²GÄé¬y©M´«¦åµ¥¤èªk¨ÃµLÀ°§U¡C ³B²zªAÃĹL¶q®É¡AÀ³¦Ò¼{¦hºØ¥ÎÃĹL¶qªº¥i¯à©Ê¡C¯S§Oª`·N¥¿¦bªA¥Î©Î³Ìªñ¦³ªA¥Î¹LCymbaltaªº¯f±w¡A¬O§_´¿ªA¥Î¹L¶qªº¤TÀô§Ü¼~Æ{¾¯¡C¦b³oºØ±¡ªp¤U¡A¤TÀô§Ü¼~Æ{¾¯¤Î/©Î¨ä¬¡©Ê¥NÁª«ªº»W¿n¡A¥i¯à¼W¥[Á{§É¤W©úÅã«á¿ò¯gªºµo¥Í²v¡A¨Ã©µªø»ÝÄY±KÆ[¹îªº®É¶¡¡C
|
ÃÄ«~«O¦s¤è¦¡ |
|
¤@¯ëÀx¦s©ó30¢J¥H¤U¡C
|